Abstract
Background: Depression is a mental disorder that affects a large part of the world's population. DHEA is a hormone that has long been attributed to the ability to improve depressive symptoms. However, few studies were conducted with depression individuals not resulting from other medical conditions.
Objective: To investigate whether DHEA is more effective than placebo in the treatment of depressive symptoms in subjects with depression not resulting from other psychiatric or medical comorbidities.
Methods: An electronic search was carried out using the keywords Dehydroepiandrosterone (Mesh) AND Depression (Mesh) in the following databases: Medical Literature databases Analysis and Retrieval System Online (Medline), Excerpta Medical Database (EMBASE), Latin American and Caribbean Health Sciences (LILACS) and the Cochrane Library through their website for relevant publications until June 2018. Only randomized clinical trials were included. The critical appraisal of the articles was performed using the Risk of Bias Tool from Cochrane Collaboration.
Results: The meta-analysis applied in this review pointed to a significant effect in favor of treatment with DHEA compared to placebo.
Conclusion: DHEA may be one more effective alternative between the drugs used in the treatment of depression.
Keywords: Dehydroepiandrosterone, DHEA treatment, depression, depression treatment, depressive disorder, depressive symptoms, mood disorders.
CNS & Neurological Disorders - Drug Targets
Title:Dehydroepiandrosterone (DHEA) for Depression: A Systematic Review and Meta-Analysis
Volume: 17 Issue: 9
Author(s): Clayton Peixoto*, Antonio Jose Grande, Mariana Bonotto Mallmann, Antonio Egídio Nardi, Adriana Cardoso and André Barciela Veras
Affiliation:
- Laboratory of Panic and Respiration, Institute of Psychiatry, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro,Brazil
Keywords: Dehydroepiandrosterone, DHEA treatment, depression, depression treatment, depressive disorder, depressive symptoms, mood disorders.
Abstract: Background: Depression is a mental disorder that affects a large part of the world's population. DHEA is a hormone that has long been attributed to the ability to improve depressive symptoms. However, few studies were conducted with depression individuals not resulting from other medical conditions.
Objective: To investigate whether DHEA is more effective than placebo in the treatment of depressive symptoms in subjects with depression not resulting from other psychiatric or medical comorbidities.
Methods: An electronic search was carried out using the keywords Dehydroepiandrosterone (Mesh) AND Depression (Mesh) in the following databases: Medical Literature databases Analysis and Retrieval System Online (Medline), Excerpta Medical Database (EMBASE), Latin American and Caribbean Health Sciences (LILACS) and the Cochrane Library through their website for relevant publications until June 2018. Only randomized clinical trials were included. The critical appraisal of the articles was performed using the Risk of Bias Tool from Cochrane Collaboration.
Results: The meta-analysis applied in this review pointed to a significant effect in favor of treatment with DHEA compared to placebo.
Conclusion: DHEA may be one more effective alternative between the drugs used in the treatment of depression.
Export Options
About this article
Cite this article as:
Peixoto Clayton *, Grande Jose Antonio , Mallmann Bonotto Mariana , Nardi Egídio Antonio, Cardoso Adriana and Veras Barciela André , Dehydroepiandrosterone (DHEA) for Depression: A Systematic Review and Meta-Analysis, CNS & Neurological Disorders - Drug Targets 2018; 17 (9) . https://dx.doi.org/10.2174/1871527317666180817153914
DOI https://dx.doi.org/10.2174/1871527317666180817153914 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Hot Topic: Monoamine Oxidase as a Target in Medicinal Chemistry and Drug Discovery)
Current Topics in Medicinal Chemistry De Novo Malignancies After Organ Transplantation: Focus on Viral Infections
Current Molecular Medicine Nitric Oxide Related Therapeutic Phenomenon: A Challenging Task
Current Pharmaceutical Design Cholinergic Targets in Lung Cancer
Current Pharmaceutical Design 5HT1F- and 5HT7-Receptor Agonists for the Treatment of Migraines
CNS & Neurological Disorders - Drug Targets Latest Progress in the Identification of Novel Synthetic Ligands for the Cannabinoid CB2 Receptor
Mini-Reviews in Medicinal Chemistry Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions
Current Topics in Medicinal Chemistry Approaches and Resources for Prediction of the Effects of Non-Synonymous Single Nucleotide Polymorphism on Protein Function and Interactions
Current Pharmaceutical Biotechnology Mesenchymal Stem Cells: A Good Candidate for Restenosis Therapy?
Current Vascular Pharmacology Markers Associated with Sex Differences in Methamphetamine-Induced Striatal Dopamine Neurotoxicity
Current Neuropharmacology Rhein-Huprine Derivatives Reduce Cognitive Impairment, Synaptic Failure and Amyloid Pathology in AβPPswe/PS-1 Mice of Different Ages
Current Alzheimer Research Signal Transduction by IL-2 and its Receptors as Target in Treatment of Rheumatoid Arthritis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Retromer Dysfunction and Neurodegenerative Disease
Current Genomics Quantum Dot-Based Nanoprobes for In Vivo Targeted Imaging
Current Molecular Medicine Influence of Leptin on Immunity
Current Immunology Reviews (Discontinued) Memantine: A Therapeutic Approach in Treating Alzheimers and Vascular Dementia
Current Drug Targets - CNS & Neurological Disorders The Role of Matrix Metalloproteinases in Essential Hypertension
Current Topics in Medicinal Chemistry Harnessing Metabolomics for Nutrition Research
Current Pharmaceutical Biotechnology Effect on Acetylcholinesterase and Anti-oxidant Activity of Synthetic Chalcones having a Good Predicted Pharmacokinetic Profile
Medicinal Chemistry Curcumin Mitigates the Fibrillation of Human Serum Albumin and Diminishes the Formation of Reactive Oxygen Species
Protein & Peptide Letters